期刊
PEDIATRIC NEPHROLOGY
卷 28, 期 10, 页码 1909-1921出版社
SPRINGER
DOI: 10.1007/s00467-012-2320-8
关键词
Histone deacetylase; HDACi; Kidney development; Kidney regeneration; Renal injury; Renal disease
资金
- National Institutes of Health (NIH) National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK) [2R01DK069403, 1RC4DK090770, 1P30DK079307]
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) [2R01HD053287]
- NIH [1RO1 HL093057-01, 1RC4DK090770-01, 1P30 DK079341]
The discovery that histone deacetylase inhibitors (HDACis) can attenuate acute kidney injury (AKI)-mediated damage and reduce fibrosis in kidney disease models has opened the possibility of utilizing HDACis as therapeutics for renal injury. Studies to date have made it abundantly clear that HDACi treatment results in a plethora of molecular changes, which are not always linked to histone acetylation, and that there is an essential need to understand the specific target(s) of any HDACi of interest. New lines of investigation are beginning to delve more deeply into target identification of specific HDACis and to address the relative toxicity of different HDACi classes. This review will focus on the utilization of HDACis during kidney organogenesis, injury, and disease, as well as on the development of these compounds as therapeutics.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据